Table 4.
Abnormal movement assessments and side effects of RLAI* and FGAI therapy
| Treatment outcome | RLAI | FGAI | P value |
|---|---|---|---|
|
Abnormal movement |
|
||
| AIMS score completed (n (%)) |
36 (51.4) |
61 (59.8) |
0.28 |
| Mean AIMS score |
1.83 |
3.25 |
0.25 |
| Proportion of patients with TD (n (%)) |
1 (1.4) |
5 (4.9) |
0.40 |
| SAS score completed |
33 (47.1) |
54 (52.9) |
0.45 |
| Mean SAS score |
2.82 |
4.85 |
0.28 |
| Proportion of patients with EPS |
12 (17.0) |
54 (52.9) |
<0.001 |
|
Side effects of therapy (n (%)) |
|
||
| Patients reporting side effects |
7 (10.0) |
17 (16.7) |
0.21 |
| EPS |
1 (14.3) |
3 (17.6) |
|
| Akathesia |
1 (14.3) |
2 (11.8) |
|
| Weight gain |
2 (28.6) |
2 (11.8) |
|
| Tremor |
0 (0) |
4 (23.5) |
|
| Galactorrhea |
1 (14.3) |
0 (0) |
|
| Other† | 2 (28.6) | 6 (35.5) | |
* Abbreviations are: RLAI Risperidone long-acting injection, FGAI First generation antipsychotic injection, AIMS Abnormal Involuntary Movement Scale, TD tardive dyskinesia, SAS Simpson Angus Scale, EPS extrapyramidal symptoms.
†Other includes injection site pain, dizziness, fatigue, TD (FGAI) and mental impairment (RLAI).